


CTC are stained blue, filter holes of 8 microns appear black.

Panel A: breast cancer, B: prostate cancer, C: colorectal cancer, D: renal/ bladder cancer

Figure 2: Histo-pathological/ cyto-morphological detection of CTC using the ISET method.

| | | | | |
|--|--|--|--|--|
| | | | | |
|--|--|--|--|--|



| | | | | | | | | | |
|--------------|----------|---------|----------------------------------|-----------------|-------------|----------|---|-------------|--|
| M22a, 76 yrs | ISET; | Feb-16; | 0.7 atypical inflammatory cells; | | normal | May-16 | 3 | Prostatitis | PSMA=PET CT: mild prostatitis; ISET-CTC identified in inflammatory condition, no CTC detected; Maintrac-CTC does not distinguish between CTC and atypical inflammatory cells |
| M22b | Maintrac | Apr-16 | 2 | PSA=79; AR=88.6 | normal | | | | |
| M23, 49 yrs | ISET; | May-16 | 65.4; | | normal | April-16 | 1 | Prostate | PSMA-PET: moderate uptake |
| | Maintrac | May-16 | 13 | AR=62; PSA=0 | | | | | |
| M24, 66 yrs | ISET; | May-16 | 10.7; | | high normal | Jun-16 | 1 | Prostate | PSMA-PET: low to moderate uptake |
| | Maintrac | | 11 | PSA=79; AR=73; | | | | | |

ISET, ISET technology (Rarecells, France, www.rarecells.com)

Maintrac technology (Germany, www.maintrac.com): Receptor expression and EpCAM marker based CTC testing. In our experience, the CTC count by Maintrac correlates to the ISET CTC count by a factor of 100. For comparison to ISET CTC counts Maintrac CTC counts have been divided by 100.

F, female; M, male, AR, androgen receptor; Ki67, the Ki-67 protein is a cellular marker for cell proliferation; PSA, prostate specific antigen; PSMA, prostate specific membrane antigen; PET scan, positron emission tomography scan; n/a, not applicable

Table 3: Early detection CTC screening and follow-up scans of asymptomatic patients without detected tumour at time of CTC testing (group 2).

| | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |




Figure 3: CTC monitoring of a) cancer patients (group1) and b) asymptomatic patients without detectable tumour (group3) before and after integrative nutritional immune-stimulating therapy.

Cancer patients (group 1) did not undergo surgery, chemo- or radiotherapy.



31. Eichbaum MH, Kaltwasser M, Bruckner T, de Rossi TM, Schneeweiss A, et al. (2006) Prognostic factors for patients with liver metastases from breast cancer. *Breast cancer res treatm* 96: 53-62.
32. Koda K, Saito N, Takiguchi N, Oda K, Nunomura M, et al. (1996) Preoperative natural killer cell activity: correlation with distant metastases in curatively